Marijo Bilusic, M.D., Ph.D. (IMAGE)
Caption
“By working across Sylvester’s Tumor Biology, Cancer Epigenetics and Translational & Clinical Oncology programs, we were able to link a well-defined molecular signal to real patient data. The result isn’t a new cancer biomarker, but a clearer understanding of how a widely used drug may support metabolic health during prostate cancer treatment—an outcome that matters to patients and clinicians alike,” said Sylvester researcher and first author, Marijo Bilusic, M.D., Ph.D.
Credit
Sylvester Comprehensive Cancer Center
Usage Restrictions
Use with attribution
License
Original content